Bupropion (Zyban) back in stock October 16th 2023
The NCSCT has completed the process of updating information on its website and e-learning programme. October 16th 2023 Bupropion (Zyban) is now back in stock and being supplied. More details to follow. The NCSCT is in the process of updating information on its website and e-learning programme.
Brugada syndrome Bupropion may unmask Brugada syndrome, a rare hereditary disease of the cardiac sodium channel with characteristic ECG changes (ST segment elevation and T wave abnormalities in the right precordial leads), which may lead to cardiac arrest and/or sudden death. Caution is advised in patients with Brugada syndrome or risk factors such as a family history of cardiac arrest or sudden death. The full Zyban Summary of Product characteristics can be found here: https://www.ncsct.co.uk/publication_bupropion.php -- On 1st December 2022 GSK placed an immediate hold on the batch release and distribution into EU markets (including the UK and Switzerland) of Zyban (bupropion hydrochloride) 150 mg prolonged release tablets. GSK has been reviewing its manufacturing processes for the potential presence of nitrosamine impurities. GSK conducted testing and the results indicate there is the potential for the presence of nnitroso-bupropion. GSK has initiated a root cause investigation is determining the best course of action. At this point it’s not possible to provide an indication of timings for the Root Cause Analysis’ completion – this is due to the complexity of the investigation. GSK will provide an update when available. On this page is an advisory document summarising alternatives to bupropion and an FAQ document that might be helpful. ![]() ![]() Back to previous page | |